Results 231 to 240 of about 1,615,435 (305)

From Interferon Signature to the Clinical Landscape: Type I Interferonopathies

Arthritis &Rheumatology, EarlyView.
Objective TypeI interferonopathies are heterogeneous diseases driven by dysregulated type I interferon (IFN‐I) signaling. Diagnosis is challenging due to clinical/molecular variability and the need for IFN‐I quantification. The aim of this study was to characterize the clinical, immunologic, genetic, molecular profiles of patients with suspected ...
Ismail Yaz, Seza Ozen, Hacer Neslihan Bildik, Canberk Ipsir, Dilara Unal, Saliha Esenboga, Begum Cicek, Mehmet Emin Seker, Fatima Aerts‐Kaya, Seher Sener, Mehmet Orhan Erkan, Hanife Avci, Deniz Cagdas, Ilhan Tezcan   +13 more
wiley   +1 more source

Reduced adenosine receptor expression in ACS patients with no-reflow phenomenon undergoing primary PCI. [PDF]

Future Cardiol
Bagheri A, Alipour Parsa S, Namazi MH, Khaheshi I, Sohrabifar N.   +4 more
europepmc   +1 more source

Effect of developmental changes on pharmacokinetics of drugs used in the treatment of infant acute lymphoblastic leukaemia—A comprehensive review

British Journal of Clinical Pharmacology, EarlyView.
While the event‐free survival (EFS) of children treated for acute lymphoblastic leukaemia (ALL) has improved greatly in the last decades, the EFS for patients diagnosed with ALL before the age of one is still under 50%. This outcome further decreases when infants have a rearrangement in the gene encoding histone‐lysine N‐methyltransferase 2A (KMT2A ...
Tirsa de Kluis, Leiah J. Brigitha, Lidwien M. Hanff, Alwin D. R. Huitema, Inge M. van der Sluis, Meta H. M. Diekstra   +5 more
wiley   +1 more source

Acute Adenosine Receptor Antagonism in Combination With Acute Intermittent Hypoxia to Promote Breathing Plasticity in Amyotrophic Lateral Sclerosis: Protocol for a Randomized, Double-Blinded, Placebo-Controlled Trial. [PDF]

JMIR Res Protoc
Sales de Campos P, Smith-Hublou M, Olsen WL, Souza Leite W, Wymer JP, Napoli NJ, Vose AK, Pulley MT, Mitchell GS, Smith BK.   +9 more
europepmc   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source

Synthesis and Biological Evaluation of 5'-Deoxy-adenosine Derivatives as A₃ Adenosine Receptor Ligands. [PDF]

ACS Med Chem Lett
Kim M, Naik SD, Choi H, Kim SW, Park JH, Joung M, Song J, Gaikwad VB, Kim M, Jeong LS.   +9 more
europepmc   +1 more source

Acute effects of THC and a CBD+THC combination on cardiovascular haemodynamics and respiratory muscle activity during loaded breathing in healthy adults: A randomized placebo‐controlled crossover study

British Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to evaluate the acute effects of cannabidiol plus tetrahydrocannabinol (CBD+THC) and tetrahydrocannabinol (THC) oils on cardiovascular haemodynamics, respiratory muscle activity and peripheral tissue perfusion in healthy adults. Methods In this randomized, double‐blind, crossover trial, participants received orally administered ...
Edna Karla Ferreira Laurentino, Marina Lyra L. C. Fagundes, Bruno Lobão Soares, Rodrigo Torres‐Castro, Matias Otto‐Yañez, Emerson Arcoverde Nunes, Matheus Freitas Fernandes Pedrosa, Jéssica Danielle Medeiros da Fonsêca, Vanessa R. Resqueti, Guilherme Augusto de Freitas Fregonezi   +9 more
wiley   +1 more source

Cantharidin attenuates the anti-β-adrenergic or anti-histaminergic or anti-serotoninergic effect of A₁-adenosine receptor stimulation in the isolated human atrium. [PDF]

Naunyn Schmiedebergs Arch Pharmacol
Schwarz R, Hofmann B, Kirchhefer U, Neumann J, Gergs U.   +4 more
europepmc   +1 more source

What Makes an “Ideal” Cell Line for Recombinant Adeno‐Associated Virus Production?

Biotechnology and Bioengineering, EarlyView.
Several host cell types have been used to produce rAAVs to date. Cell line‐specific traits that are beneficial in the context of rAAV manufacturing are reviewed here, with the goal of developing a consensus on the ‘ideal’ characteristics that an rAAV production host should possess (created with Biorender.com).
James Conheady, Nicholas Donohue, Alexandra Bogdanovic, Sharon Davin, Brian Glennon, Niall Barron, C. Mark Smales   +6 more
wiley   +1 more source